Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico , in vitro and in vivo evaluation

Devasari, Naresh; Dora, Chander Parkash; Singh, Charan; Paidi, Sharan Reddy; Kumar, Vivek; Sobhia, M. Elizabeth; Suresh, Sarasija

doi:10.1016/j.carbpol.2015.08.012

Cited by 88 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4a-d). Protons of SBE 7 -b-CD NF and as-received powder SBE 7 -b-CD were appeared in the range of d 1.5-5.8 ppm which is correlated with previous literature (Devasari et al, 2015;Kulkarni and Belgamwar, 2017). As shown in Fig.…”

Section: Structural Characterization Of Sbe 7 -B-cd Nf and Sulfisoxazsupporting

confidence: 90%

Polymer-free electrospun nanofibers from sulfobutyl ether 7 -beta-cyclodextrin (SBE 7 -β-CD) inclusion complex with sulfisoxazole: Fast-dissolving and enhanced water-solubility of sulfisoxazole

Yıldız

Çelebioğlu

Uyar

2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

In this study, our aim was to develop solid drug-cyclodextrin inclusion complex system having nanofibrous morphology in order to have fast-dissolving property and enhanced water-solubility of poorly water-soluble drug. Here, we prepared a highly concentrated aqueous solution of inclusion complex between sulfisoxazole and sulfobutyl ether-beta-cyclodextrin (SBE-β-CD, Captisol), and then, without using any polymeric matrix, the electrospinning of sulfisoxazole/SBE-β-CD-IC nanofibers was performed in order to obtain free-standing and handy nanofibrous web. As a control sample, nanofibers from pure SBE-β-CD was also electrospun and free-standing nanofibrous web was obtained. The SEM imaging revealed that the bead-free and uniform nanofiber morphology with the average fiber diameter (AFD) of 650±290nm for sulfisoxazole/SBE-β-CD-IC NF and 890±415nm for pure SBE-β-CD NF was obtained. The inclusion complex formation between sulfisoxazole and SBE-β-CD in sulfisoxazole/SBE-β-CD-IC NF sample was confirmed by H NMR, TGA, DSC, XRD and FTIR analyses. Due to the combined advantage of cyclodextrin inclusion complexation and high surface area of electrospun nanofibers, fast-dissolving property with enhanced water-solubility was successfully achieved for sulfisoxazole/SBE-β-CD-IC NF. Our findings suggest that electrospun nanofibers/nanowebs from CD-IC of poorly water-soluble drugs may offer applicable approaches for high water-solubility and fast-dissolving tablet formulations for drug delivery systems.

show abstract

Section: Structural Characterization Of Sbe 7 -B-cd Nf and Sulfisoxazsupporting

confidence: 90%

Polymer-free electrospun nanofibers from sulfobutyl ether 7 -beta-cyclodextrin (SBE 7 -β-CD) inclusion complex with sulfisoxazole: Fast-dissolving and enhanced water-solubility of sulfisoxazole

Yıldız

Çelebioğlu

Uyar

2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Unfortunately, it was not possible to see this expected correlation contour by the NOESY spectrum. On the other hand, it was reported that 20 ROESY experiment has been used for the structure elucidation of inclusion complex of Erlotinib with sulfobutyl ether-β-cyclodextrin, hencewe have also run the ROESY spectra. Actually, in the ROESY spectrum of Erlotinib HCl (Figure 3), the NH proton signal at δ11.6 ppm gives NOE with the peak at δ 8.50 ppm.…”

Section: Resultsmentioning

confidence: 99%

Total Structural Elucidation of Erlotinib and Gefitinib by Mainly 2D-Rotating Frame Overhauser Effect Spectroscopy (2D ROESY NMR)

2017

Chem Sci Trans

View full text Add to dashboard Cite

show abstract

“…Therefore, the most important strategy to improve bioavailability of the class II and IV is their dissolution enhancement. The main approaches in order to increase dissolution rate, are particle size reduction, self-emulsification, cyclodextrin complexation, crystal modification and amorphous solid dispersion (61)(62)(63)(64).…”

Section: Solubility Modification Of Tkismentioning

confidence: 99%

Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors

Moradpour

Barghi

2019

J Pharm Pharm Sci

View full text Add to dashboard Cite

Epidermal growth factor receptors (EGFRs) have potential to be considered as therapeutic target for cancer treatment especially in cancer patients with overexpression of EGFR. Cetuximab as a first monoclonal antibody and Imatinib as the first small molecule tyrosine kinase inhibitor (SMTKI) were approved by FDA in 1998 and 2001. About 28 SMTKIs have been approved until 2015 and a large number of compound with kinase inhibitory activity are at the different phases of clinical trials. Although Kinase inhibitors target specific intracellular pathways, their tissue or cellular distribution are not specific. So treatment with these drugs causes serious dose dependent side effects. Targeted delivery of kinase inhibitors via dendrimers, polymeric nanoparticles, magnetic nanoparticles and lipid based delivery systems such as liposomes, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) can lead to reduction of side effects and improving therapeutic efficacy of the drugs in the target organs. Furthermore formulation of these drugs is challenged by their physicochemical properties such as solubility and dissolution rate. The main approaches in order to increase dissolution rate, are particle size reduction, self-emulsification, cyclodextrin complexation, crystal modification and amorphous solid dispersion. Synergistic therapeutic effect, decreased side effects and drug resistant, reduced cost and increased patient compliance are the advantages associated with using combination therapy especially in the treatment of cancer. Combination of TKIs with chemotherapeutic agents or biopharmaceuticals such as monoclonal antibodies and oligonucleotides and also combination of two TKIs within one formulation is possible by new targeting delivery systems. This article reviews the recent advances in the design and development of delivery systems for TKIs.

show abstract

Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico , in vitro and in vivo evaluation

Cited by 88 publications

References 31 publications

Polymer-free electrospun nanofibers from sulfobutyl ether 7 -beta-cyclodextrin (SBE 7 -β-CD) inclusion complex with sulfisoxazole: Fast-dissolving and enhanced water-solubility of sulfisoxazole

Polymer-free electrospun nanofibers from sulfobutyl ether 7 -beta-cyclodextrin (SBE 7 -β-CD) inclusion complex with sulfisoxazole: Fast-dissolving and enhanced water-solubility of sulfisoxazole

Total Structural Elucidation of Erlotinib and Gefitinib by Mainly 2D-Rotating Frame Overhauser Effect Spectroscopy (2D ROESY NMR)

Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors

Contact Info

Product

Resources

About